Pfizer’s DMD Setback With Domagrozumab Shifts Focus To Gene Therapy Approach

With its first AAV gene therapy candidate from Bamboo Therapeutics expected to report data in 2019, Pfizer’s efforts to get in the DMD competition now center on that modality.